Zhao J, Young YK, Fradette J, Eliopoulos N. Melatonin pretreatment of human adipose tissue-derived mesenchymal stromal cells enhances their prosurvival and protective effects on human kidney cells.
-The efficacy of cell therapy for many diseases can be limited by the poor survival of implanted cells in an environment of tissue injury. Melatonin has been reported to have antioxidative and antiapoptotic effects. Adipose tissue-derived mesenchymal stromal cells (ASCs), cells easily obtained in high amounts and with minimal discomfort, have shown great promise in cell therapy applications, such as in acute kidney injury. We hypothesized that melatonin pretreatment of human ASCs (hASCs) would improve their renoprotective and prosurvival effects. We therefore investigated the action of melatonin on hASCs, as well as the effect of the resulting hASCs-conditioned media (CM) on human kidney cells exposed to oxidative and apoptotic injuryprovoking doses of cisplatin. Our results demonstrated that pretreatment of hASCs with melatonin, 100 M for 3 h, significantly increased their proliferation and their expression of prosurvival P-Erk1/2 and P-Akt, and of antioxidative enzymes catalase and heme oxygenase (HO)-1. In addition, the CM from hASCs pretreated with melatonin provoked a significantly higher proliferation and migration of HK-2 human kidney epithelial cells. Furthermore, this CM exerted significantly higher prosurvival and antiapoptotic actions on HK-2 cells exposed to cisplatin in vitro. Western blot analysis showed higher expression of P-Erk1/2, Bcl-2, SOD-1, and HO-1 in the HK-2 cells exposed to cisplatin in the presence of CM from melatoninpretreated hASCs. In sum, our study revealed that in vitro pretreatment of hASCs with melatonin may significantly enhance their survival and their therapeutic effectiveness on injured tissue. kidney cells; melatonin; mesenchymal stromal cells; adipose tissue; stem cells MESENCHYMAL STROMAL CELLS, also commonly referred to as mesenchymal stem cells (MSCs), have shown great promise in cell therapy and regenerative medicine applications. Although initial studies focused on MSCs derived from bone marrow, it is now known that these cells can also be isolated from other tissues, such as adipose tissue, periosteum, dermis, synovial fluid, amniotic fluid, placenta, and umbilical cord blood (28, 46) . These cells are beneficial for many reasons. Other than for their ability to differentiate into a large variety of cell types, MSCs have numerous medical applications due to their paracrine effects. The secretome of MSCs has been shown to exert mitogenic, antiapoptotic, anti-inflammatory, and angiogenic effects on damaged tissue (9, 20) . Clinical uses of MSCs include cardiovascular, orthopedic, spinal cord, neural, and autoimmune diseases, as well as wound healing (28) .
One application of MSCs has been in acute kidney injury (AKI), where several studies, including ours, have demonstrated the potential of bone marrow-derived MSCs for renal protection and repair in AKI resulting from toxic and/or ischemic insult (2, 11, 12, 16, 21, 27, 38, 39 ). An alternative source of MSCs for kidney repair are adipose tissue-derived stromal/ stem cells (ASCs) (15) . Advantages of using ASCs include their ability to be isolated in high amounts and the minor discomfort to the donor. ASCs are similar to bone marrowderived MSCs, sharing many cell surface markers and clinical potential (17, 26, 29, 47) . Studies have shown the effect of rodent ASCs in decreasing renal damage in models of ischemia-reperfusion-induced AKI (8, 14) . Other than ischemiareperfusion, one agent commonly used to induce kidney injury is cisplatin. Cisplatin is a very effective drug commonly used in various cancer chemotherapies, but it has toxic effects on several normal tissues (1, 10, 30) . Nephrotoxicity is the side effect which limits cisplatin therapy the most and, since dose dependent, it restricts its therapeutic potential (1, 10, 18) . In cisplatin-induced AKI rodent models, ASCs have demonstrated renoprotective abilities (2, 24) . More specifically, one study reported that the administration of human ASCs (hASCs), or of their conditioned media (CM), led to renoprotective and prosurvival effects in a rat model of cisplatininduced AKI (24) .
Cisplatin has been reported to cause oxidative and apoptotic injury (10, 18) . In fact, many pathological states are characterized by tissue damage, such as due to oxidative stress. Cell therapy effectiveness thus for many diseases is limited by the weak survival of implanted cells in such environments (5, 35) . Therefore, approaches to enhance cell survival and thus therapeutic effectiveness of cell therapy are of great interest. One strategy for improving cell therapy is to pretreat, hence precondition, the cells ex vivo with a pharmacological agent with beneficial properties, such as with melatonin, to improve implanted cell survival and to decrease their apoptosis. Melatonin, a compound primarily produced by the pineal gland, has been reported to exert many antioxidative and antiapoptotic effects (31, 34) . Moreover, ASCs have also been shown to have antioxidative and antiapototic actions (8) .
We therefore hypothesized that treating hASCs with melatonin would augment the protective actions of these cells on human kidney cells exposed to cisplatin toxicity. One study using rat bone marrow-derived MSCs pretreated with melatonin showed their increased beneficial effects when administered in rats with ischemia-reperfusion-induced AKI (25) . Knowing that cisplatin toxicity affects primarily the renal proximal tubules (44), we used the HK-2 human kidney cortex proximal tubular cell line in the present investigation. In brief, we demonstrated in this study that hASCs pretreated with melatonin have enhanced proliferation and migration, and that their CM, i.e., secretome, exerts higher prosurvival and antiapoptotic effects on human HK-2 cells exposed to cisplatin.
MATERIALS AND METHODS
Cell culture conditions. hASCs were isolated as previously described (40) and kindly provided by Dr. Julie Fradette (Université Laval, LOEX, Quebec City, Quebec). More specifically, as approved by the ethics committee, these ASCs were isolated from subcutaneous fat lipoaspirated for cosmetic purposes from three women aged 38, 40, and 46 (identified as LA38, LA40, and LA46, and in this study as donor 1, 2, and 3, respectively) with a mean body mass index of 22.4 Ϯ 2.8 (SD). Cryopreserved hASCs were thawed and plated in 15-cm diameter plates (Becton Dickinson Falcon, Franklin Lakes, NJ) at 6,000 cells/cm 2 in complete media consisting of DMEM/F12 (Invitrogen-GIBCO, Carlsbad, CA) supplemented with 10% FBS (Wisent, St.-Bruno, Quebec) and 100 U/ml penicillin, 100 g/ml streptomycin (Pen/Srep, Wisent). Media was changed every 2-3 days until the cells reached 80% confluence, and then cells were passaged and used for our experiments at passage 3-5. Throughout the experiments, cells were kept in a humidified 37°C incubator with 5% CO 2.
Proliferation assay on hASCs. hASCs were seeded in 24-well plates (Becton Dickinson, Falkon) at 300 cells/cm 2 in complete media. The next day, the media were changed to serum-free media. After serum starvation for 18 h to synchronize cells as reported by others (7), the cells were pretreated or not with melatonin (SigmaAldrich, Oakville, Ontario) at 100 M for 3 h in complete media. Following this, media were removed and cells were rinsed twice with Dulbecco's PBS (DPBS; Wisent) and maintained in complete media (with media changes once per day). After 8 days in culture, a proliferation assay was performed on these hASCs using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich), as described by the manufacturer.
Western blot analysis of hASCs. hASCs pretreated or not with melatonin at 100 M for 3 h in complete media were collected and lysed, and whole cell lysates were analyzed by Western blotting to asses the expression of phospho-Erk1/2 (P-Erk1/2), phospho-Akt (P-Akt), catalase, glutathione peroxidase 1 (GPx1), and heme oxygenase (HO)-1 in nontreated, melatonin-treated hASCs from all three donors, and in the presence and absence of melatonin receptor antagonists. More specifically, hASCs were starved in serum-free media for 18 h and then pretreated with luzindole (R&D Systems), a competitive MT 1/MT2 melatonin receptor antagonist, at a concentration of 10 M, or with 4-phenyl-2-propionamidotetralin (4-P-PDOT; R&D Systems), a melatonin MT 2 antagonist, at a concentration of 20 M, or with both these antagonists for 1 h before addition of melatonin (at 100 M for 3 h). These cells were then washed well with DPBS, collected, and lysed using a lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM Na 3VO4, 1 g/ml leupeptin, and 1 mM PMSF]. Protein concentrations were determined with a Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). Whole cell lysates containing 15-30 g total protein were separated by 4 -20% Precise Protein Gels (Thermo Scientific, Rockford, IL) and transferred to nitrocellulose membranes (Bio-Rad Laboratories). The membranes were then incubated for 1 h at room temperature in the solution of TBST [10 mM Tris·HCl (pH 8.0), 150 mM NaCl, and 0.05% Tween 20] supplemented with 10% nonfat dry milk. Subsequently, the membranes were probed overnight at 4°C with primary antibodies of P-Erk1/2, P-Akt, catalase, GPx1 (Cell Signaling Technology, Beverly, MA), and HO-1 (R&D Systems, Minneapolis, MN). The membranes were then washed with TBS containing 0.1% Tween 20. The bound primary antibodies were visualized by incubating for 1 h with a suitable secondary antibody conjugated with horseradish peroxidase (Bethyl Laboratories, Montgomery, TX). The membranes were washed and developed using Chemiluminescent HRP Substrate (ZmTech Scientific, Montreal, Quebec). Blots were later stripped with Re-Blot Plus Strong Solution (Millipore, Temecula, CA) or Western Blot Stripping Buffer (ZmTech Scientific) and reprobed with antibodies against total Erk (Santa Cruz Biotechnology, Santa Cruz, CA), total Akt, or GAPDH (Cell Signaling Technology) as a loading control.
Preparation of CM from hASCs. hASCs were seeded at 5,000 cells/cm 2 in tissue culture plates and incubated in complete media. The next day, hASCs were incubated in the absence or presence of melatonin at 100 M for 1, 3, 6, 18, or 24 h. Cells were then washed with DPBS and incubated in complete media at 0.15 ml/cm 2 for 120 h. The CM were then collected and, after any debris removed by centrifugation, saved for experiments for HK-2 cell proliferation, migration, and cytotoxicity, as well as terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) and Western blot assays.
Proliferation assay of HK-2 human kidney cells. HK-2 human kidney cortex proximal tubular cells (ATCC, Manassas, VA) were plated at 1 ϫ 10 4 cells/well in 24-well plates in Keratinocyte SerumFree Media (K-SFM; Invitrogen) supplemented with bovine pituitary extract (0.05 mg/ml) and human recombinant epidermal growth factor (5 ng/ml, Invitrogen). After 24 h, the media was replaced at 0.5 ml/well with either DMEM/F12 complete media, CM of hASCs, or CM of hASCs pretreated with melatonin (at 100 M for 3 h). The HK-2 cells were then cultured for 5 days, following which their cell proliferation was assessed by MTT assay. The results were then normalized to the mean proliferation in the control DMEM/F12 complete media.
Migration assay of HK-2 cells. HK-2 cells were culture-expanded to 100% confluent monolayers in six-well plates. A linear wound was then made by uniformly scratching with a pipette tip. Cells were then rinsed with DPBS to wash away any cellular debris and/or detached cells. The cells were then cultured in DMEM/F12 complete media, CM of hASCs, or CM of hASCs pretreated with melatonin (at 100 M for 3 h). After 18 h of culture, the cells were visualized and photographed under brightfield microscopy with a Leica DMIL microscope. Migration was quantified by counting the number of cells that had migrated into the denuded area in each randomly chosen microscope field. At least 14 fields were counted per group.
Cytotoxicity assay of HK-2 cells. HK-2 cells were seeded at 3 ϫ 10 4 cells/cm 2 . The next day, the media was replaced with DMEM/F12 complete media, CM of hASCs, or CM of hASCs pretreated with melatonin (at 100 M for 3 h) (Sigma-Aldrich), in the absence or presence of cisplatin (Mayne Pharma Canada, Montreal, Quebec) at 12.5 g/ml. After 42 h in culture, cell viability was measured by MTT assay (Sigma-Aldrich).
TUNEL assay of HK-2 cells. HK-2 cells were seeded in four-well Lab-Tek II Chamber Slides (Thermo Fisher Scientific, Naperville, IL) at 1 ϫ 10 5 cells/well. The next day, the cells were treated with DMEM/F12 complete media, CM of hASCs, or CM of hASCs pretreated with melatonin (at 100 M for 3 h), in the presence of cisplatin at 7 g/ml for 20 h. The cells treated with complete media without cisplatin (Mayne Pharma) served as a negative control. Then, the apoptotic cells were evaluated by TUNEL assay according to the manufacturer's instructions (In situ Cell Death Detection Kit, TMR red; Roche Diagnostics, Indianapolis, IN). Briefly, after washing of the cells three times with DPBS, they were fixed with 4% paraformaldehyde solution in DPBS for 1 h and permeabilized with 0.2% Tween 20 in DPBS for 1 h. Fixed cells were then incubated in TUNEL reaction media (50 l) for 1 h at 37°C in the dark. After the reaction was stopped, total cell numbers were determined by counterstaining with 4=,6-diamidino-2-phenylindole (DAPI; Invitrogen, Eugene, OR). Slides were mounted with Gold Antifade Reagent (Cell Signaling Technology). Fluorescent slides were viewed using a Leica DM LB2 microscope (Leica Microsystems, Bannockburn, IL) and images acquired by Leica Application Suite Version 3.40 software (Leica Microsystems). Over 10 random fields/well were photographed. The number of TUNEL-positive and DAPI-stained cells were counted with ImageJ software.
Western blot analysis of HK-2 cells. HK-2 cells were seeded at 3 ϫ 10 4 cells/cm 2 . The next day, the media was replaced by DMEM/F12 complete media, CM of hASCs, or CM of hASCs pretreated with melatonin, in the presence of cisplatin (Mayne Pharma) at 12.5 g/ml. After 42 h of culture, all cells (adherent and floating) were collected and lysed, and the lysates were analyzed as described above for the primary antibodies of P-Erk1/2, SOD-1, Bcl-2 (Cell Signaling Technology), and HO-1 (R&D Systems). Blots were later stripped and reprobed with anti-total Erk or anti-GAPDH antibody as a loading control, as described above.
Statistical analysis. One-way ANOVA followed by Bonferroni's post hoc multiple comparison test were used for all experiments of three groups or more. Each P value was adjusted to account for multiple comparisons. In one experiment of two groups, an unpaired t-test was utilized for comparison. In all cases, P Յ 0.05 was deemed statistically significant.
RESULTS

Similar phenotypes of nontreated hASCs and melatonintreated hASCs.
To ascertain that nontreated hASCs and melatonin-treated hASCs express the cell surface antigens characteristic of mesenchymal stromal cells, flow cytometry analysis was performed. Our findings (data not shown) demonstrate that nontreated hASCs as well as melatonin-treated hASCs are Fig. 1 . Effect of melatonin on human adipose tissue-derived stromal/stem cells (hASCs) proliferation. Human ASCs were serum-starved for 18 h to synchronize cells and then treated or not with melatonin at 100 M for 3 h in complete media. Nontreated hASCs (NT-hASCs) and melatonin-treated hASCs (MelhASCs) were then maintained in complete media for 8 days, after which an MTT assay was performed. The experiment was conducted with 3 different donor hASCs preparations. NT-hASCs: 95% confidence interval (CI) of the mean: 0.953-1.063 (n ϭ 12); Mel-hASCs: 95% CI of the mean: 1.084 -1.396 (n ϭ 6). Student's t-test was conducted. Three donor hASC preparations were exposed to either melatonin receptor antagonist luzindole, 4-P-PDOT, or both combined for 1 h, and then treated or not with melatonin at 100 M for 3 h. Lysates were isolated, and Western blot analyses were conducted to determine expression of P-Erk1/2 and total Erk (A), P-Akt and total Akt (B), catalase (C), GPx1 (D), HO-1 (E), and loading control (GAPDH), as described in MATERIALS AND METHODS.
positive for CD44, CD73, CD90, and CD105 and negative for CD31, CD34, CD45, and HLA-DR (MHCII).
To assess whether melatonin treatment impacted cell differentiation potential, nontreated hASCs and melatonin-treated hASCs were exposed in vitro to specific osteogenic and adipogenic differentiation-inducing media. Our results (data not shown) demonstrate that both these cell populations have similar osteogenic and adipogenic differentiation abilities as revealed following alizarin red S and oil red O staining, respectively.
Expression of melatonin receptors by hASCs. To assess whether the hASCs expressed melatonin receptor 1 (MT 1 ) and melatonin receptor 2 (MT 2 ), Western blot analysis was conducted. Our results revealed (data not shown) that G proteincoupled high-affinity MT 1 and MT 2 are expressed by the hASCs.
Enhanced hASCs proliferation by melatonin. To determine whether melatonin pretreatment of hASCs affects their proliferation, hASCs, serum-starved for 18 h to synchronize cells, were pretreated or not with melatonin for 3 h, and their proliferation was then assessed by MTT assay. As shown in Fig. 1 , proliferation of melatonin-treated hASCs was significantly higher (P Ͻ 0.0005), i.e., 1.23 Ϯ 0.05-fold greater, than that of nontreated hASCs (1.00 Ϯ 0.02).
Increased prosurvival protein expression in hASCs by melatonin and effect of melatonin receptor antagonists. To further study the prosurvival effect exerted by melatonin treatment of hASCs, several Western blot analyses were conducted in nontreated and melatonin-treated hASCs to determine the expression of prosurvival, antiapoptotic, and antioxidative proteins (Fig. 2) , and to first determine the optimal duration of melatonin exposure (data not shown). When melatonin was used at 100 M, treatment of hASCs for 1 or 3 h led to the strongest increases in P-Erk1/2 expression compared with levels seen in nontreated cells. With regard to SOD-1, expression appears highest at the 3-h duration of melatonin treatment. Catalase expression required at least 3 h to surpass levels observed in nontreated cells, whereas peak HO-1 expression in hASCs occurred with 6-h exposure to melatonin (data not shown).
Three donor hASCs preparations were used to reveal any effect of melatonin, in the absence and presence of melatonin receptor antagonists, on survival signaling proteins expression. Western blot analysis was conducted in these hASCs following their exposure or not to melatonin and to melatonin receptor antagonist luzindole and/or 4-P-PDOT. As shown in Fig. 2A , P-Erk1/2 expression was substantially increased by melatonin treatment of hASCs from all three donors. This increased P-Erk1/2 expression was decreased by luzindole in melatonintreated hASCs from donor 3, by P-PDOT in melatonin-treated hASCs from donor 2, and by the combination of luzindole and P-PDOT in melatonin-treated hASCS from donors 2 and 3 and less so from donor 1 (Fig. 2A) .
Similarly, P-Akt expression was increased by melatonin treatment of hASCs from all three donors (Fig. 2B ). This increased P-Akt expression was lowered by luzindole in melatonin-treated hASCs from donor 3, by P-PDOT in melatonintreated hASCs from donors 1 and 2, although less so, and by the combination of luzindole and P-PDOT in melatonin-treated hASCs from all three donors (Fig. 2B) .
Furthermore, as shown in Fig. 2C , catalase expression was augmented by melatonin treatment of hASCs from all three donors. This increased catalase expression was decreased by luzindole in melatonin-treated hASCs from donor 3, by P-PDOT in melatonin-treated hASCs from donor 3 and from donor 2, and more notably by the combination of luzindole and P-PDOT in melatonin-treated hASCS from donors 2 and 3, and less so from donor 1 (Fig. 2C) .
Moreover, as seen in Fig. 2 , GPx1 expression was increased by melatonin treatment of hASCs from donor 3 and less so from donor 2 (Fig. 2D) . This increased GPx1 expression was lowered by luzindole as well as by P-PDOT in melatonintreated hASCs from donor 3, and by the combination of luzindole and P-PDOT in melatonin-treated hASCS from donors 2 and 3 (Fig. 2D) .
Last, HO-1 expression was augmented by melatonin treatment of hASCs from all three donors (Fig. 2E) . This increased HO-1 expression was decreased by luzindole and more so by P-PDOT in melatonin-treated hASCs from donor 3, and more notably by the combination of luzindole and P-PDOT in melatonin-treated hASCs from donor 2 and more so from donor 3 (Fig. 2E) .
Enhanced HK-2 cell proliferation by CM from melatonintreated hASCs. Since therapeutic effects of MSCs are often mediated through their secretome, to determine any effect of the CM from nontreated as well as from melatonin-treated hASCs on human kidney cell proliferation, HK-2 human renal proximal tubular cells were exposed to these CM or regular media for 5 days and their proliferation was determined by MTT assay. As evident in Fig. 3 , HK-2 cell proliferation increased by 1.08 Ϯ 0.02-fold and significantly by 1.16 Ϯ 0.04-fold when exposed to CM from nontreated hASCs and Fig. 3 . Effect of CM from hASCs and melatonin-treated hASCs on proliferation of HK-2 human kidney proximal tubular cells. The proliferation of HK-2 cells was analyzed by MTT assay after culturing of these cells for 5 days in either media (Media), CM from nontreated hASCs (NT-hASCs-CM), or CM from hASCs pretreated with melatonin at 100 M for 3 h (Mel-hASCS-CM), as described in MATERIALS AND METHODS. The results were normalized to the mean proliferation in the control Media group. The experiment was conducted with 3 different donor hASCs preparations. Media: 95% CI of the mean: 0.9527-1.072 (n ϭ 6); NT-hASCs-CM: 95% CI of the mean: 1.026 -1.139 (n ϭ 12); Mel-hASCs-CM: 95% CI of the mean: 1.088 -1.315 (n ϭ 12). One-way ANOVA followed by Bonferroni's post hoc multiple comparisons test were conducted. Each P value was adjusted to account for multiple comparisons.
melatonin-treated hASCs, respectively, compared with when regular media was used (P ϭ 0.55 and P Ͻ 0.005, respectively). Moreover, this enhancement of HK-2 cell proliferation obtained with CM from melatonin-treated hASCs was significantly higher than that seen with CM from nontreated hASCs (P Ͻ 0.05) (Fig. 3) .
Enhanced HK-2 cell migration by CM from melatonintreated hASCs. To reveal any effect of the CM from nontreated and melatonin-treated hASCs on migration of human kidney cells, the migration of HK-2 human proximal tubular cells exposed to these CM or regular media was determined by an in vitro scratch assay as described above. In brief, the migration of HK-2 cells into the denuded scratched area of the confluent culture plates was quantified 18 h after scratching. As observed in Fig. 4A , HK-2 cell migration was highest when these kidney cells were exposed to the CM from the melatonin-treated hASCs. More specifically, the number of HK-2 cells that had migrated into the denuded area in 18 h was 522 Ϯ 7.3 with the use of CM from melatonin-treated hASCs, a value significantly higher than that seen with nontreated hASCs CM (420 Ϯ 5.1, P Ͻ 0.0001), or with media alone (296 Ϯ 8.8, P Ͻ 0.0001) (Fig. 4B ).
Higher HK-2 cell survival by CM from melatonin-treated hASCs. To assess whether melatonin treatment of hASCs increases the cytoprotective effect of hASCs CM, HK-2 human proximal tubular cells were exposed to cisplatin in the presence of CM from nontreated or melatonin-treated hASCs for 42 h, and effects were compared with that seen with regular culture media only. As evident in Fig. 5 , HK-2 cell survival in the presence of cisplatin was only 17.8 Ϯ 1.3% with regular media, but significantly higher with use of CM from nontreated hASCs, i.e., 37.3 Ϯ 3.6% (P Ͻ 0.0005), or CM from melatonin-treated hASCs, i.e., 51.6 Ϯ 4.3% (P Ͻ 0.0001). Furthermore, this enhancement of HK-2 cell survival observed with CM from melatonin-treated hASCs was significantly higher than that seen with CM from nontreated hASCs (P Ͻ 0.01) (Fig. 5) .
Reduced HK-2 cell apoptosis by CM from melatonin-treated hASCs. To determine any antiapoptotic effect of the CM from nontreated as well as melatonin-treated hASCs on human kidney cells exposed to cisplatin, a TUNEL assay was conducted. As seen in One-way ANOVA followed by Bonferroni's post hoc multiple comparisons test were conducted. Each P value was adjusted to account for multiple comparisons.
vs. 21.5 Ϯ 0.6% (P Ͻ 0.0001), respectively. Notably, CM from melatonin-treated hASCs significantly decreased even further the percentage of apoptotic HK-2 cells compared with CM from nontreated hASCs, i.e., 4.9 Ϯ 0.3 vs .11.3 Ϯ 0.4% (P Ͻ 0.0001), respectively.
Increased prosurvival protein expression in HK-2 cells by CM from melatonin-treated hASCs.
To find a contributing mechanism for the prosurvival effects of the hASCs CM on HK-2 cells exposed to cisplatin, several Western blot analyses were carried out using these kidney cells. As revealed in Fig. 7 , CM from nontreated hASCs led to an increase in P-Erk1/2 expression in HK-2 cells exposed to cisplatin, compared with regular culture media only, but not as high as that seen with use of CM from 3-h melatonin-treated hASCs (Fig. 7A) . This was also the case with the expression of SOD-1, where again 3-h melatonin-treated hASCs led to the highest levels of SOD-1 in HK-2 cells exposed to cisplatin (Fig. 7B) . Furthermore, a weak, but still higher HO-1 expression level was seen with CM from 3-h melatonin-treated hASCs compared with CM from nontreated hASCs (Fig. 7C) . In addition, Bcl-2 expression in HK-2 cells appeared greatest with use of CM from 3-h melatonintreated hASCs, especially compared with CM from nontreated ASCs (Fig. 7D) .
DISCUSSION
In this study, we evaluated the action of melatonin on hASCs in vitro, showed the effect of the secretome, hence of the CM from melatonin-treated or untreated hASCs, on human renal tubular cells exposed to cisplatin toxicity, and revealed potential mechanisms involved in the observed outcomes.
In brief, we first noted that melatonin treatment significantly enhanced the proliferative capacity of hASCs. Since melatonin has been reported to act at least partly through melatonin receptors (31), we then demonstrated by Western blotting the expression of the MT 1 and MT 2 melatonin receptor subtypes on hASCs. This finding is in accord with a study where RT-PCR showed the expression of these receptor subtypes on rat bone marrow-derived-MSCs (25) . We next determined that the prosurvival action of melatonin on hASCs is through P-Erk1/2 and P-Akt signaling pathways of the melatonin membrane receptors MT 1 and MT 2 . In all the three donor hASCs preparations we examined, melatonin pretreatment increased the expression of P-Erk1/2, P-Akt, catalase, and HO-1, observations consistent with melatonin's reported abilities (31, 34) . Although we saw differences between the different donor hASCs with regards to their response to the melatonin receptor antagonists, pointing to their heterogeneity, we noted that the melatonin actions are at least partly attributed to the expression of melatonin receptors on hASCs. This supports the published suggestion that melatonin has both receptor-dependent as well as receptor-independent effects (31, 34, 36) .
Since the advantages of ASCs appear to be primarily due to the beneficial factors they secrete (3, 4, 13), i.e., to their paracrine effects, the CM of these cells may be an alternative to stem cell transplantation (23, 29) . We here demonstrated that the proliferation and migration of HK-2 human kidney proximal tubular cells were significantly elevated by the CM of hASCs, and that melatonin pretreatment of hASCs significantly enhanced these effects mediated by the CM. These findings are consistent with reported results using rat marrow MSCs, where increased proliferation of rat renal proximal tubular cells was induced in vitro by their exposure to CM from melatonin-treated MSCs (25) .
Cisplatin has been reported to cause oxidative and apoptotic injury (10, 18) . Consequently, a protective strategy such as through hASCs, and particularly melatonin-pretreated hASCs, may improve the therapeutic effectiveness of cisplatin and of other drugs with similar toxicities. The effect of nontreated hASCs was evaluated in an earlier investigation, which revealed that after exposure to cisplatin, HK human kidney proximal tubular cells exposed to hASCs CM or cocultured with hASCs showed significantly higher viability compared with the controls (24) . Using marrow-derived MSCs, we and others have previously shown that the CM from these cells exert a prosurvival effect on renal tubular cells exposed to cisplatin in vitro (2, 11, 12) . We now here reveal using hASCs that their pretreament with melatonin provided their CM an even significantly greater ability than that of nontreated hASCs to increase survival and reduce apoptosis of cisplatin-treated HK-2 human renal cells. Moreover, we also observed that melatonin pretreatment of hASCs resulted in CM capable of increasing the expression of several prosurvival, antiapoptotic and antioxidative proteins, such as P-Erk 1/2, SOD-1, HO-1, and Bcl-2, in HK-2 cells exposed to cisplatin. Our findings are in accord with the reported numerous actions of melatonin, which include apoptosis prevention, antioxidative effect, and prosurvival action (25, 31, 41) . For instance, in vitro studies using rodent marrow MSCs showed the protective action of melatonin against hydrogen peroxide oxidative stress-induced apoptosis of these cells and indicated that this effect was at least partly mediated by melatonin receptor stimulation (25, 41) . After 42 h, HK-2 cell survival was determined by MTT assay. HK-2 cells exposed to media and no cisplatin served as the control (Ctrl). The experiment was conducted with 3 different donor hASCs preparations. Media: 95% CI of the mean: 14.8 -20.8% (n ϭ 9). NT-hASCs-CM: 95% CI of the mean: 29 -45.7% (n ϭ 9). Mel-hASCs-CM: 95% CI of the mean: 41.6 -61.5% (n ϭ 9). One-way ANOVA followed by Bonferroni's post hoc multiple comparisons test were conducted. Each P value was adjusted to account for multiple comparisons.
Our results presently revealing that melatonin pretreatment of hASCs significantly ameliorates their beneficial effects suggest promising follow-up in vivo investigations. In previous in vivo studies, we and others used nontreated human marrowderived MSCs and showed the effectiveness of these cells when delivered in immunodeficient mice with cisplatin-induced AKI to decrease mouse mortality and protect renal function (11, 27) . Other reports have shown the therapeutic potential of ASCs in kidney injury models (8, 14, 43) . In brief, mouse and rat ASCs provided renoprotective effects when administered in rodents subjected to kidney ischemia-reperfusion injury (8, 14, 43) . Observations included antiapoptotic, antioxidative, and anti-inflammatory effects (8, 14, 43) . Furthermore, in a model of cisplatin-induced AKI, mouse ASCs, as well as their CM, showed protective effects by decreasing kidney injury and tubular cell apoptosis, and increasing mouse survival (2) . With regard to human ASCs for renal protection/ repair, one study demonstrated their ability to protect recipient nude rats from folic acid-induced kidney injury and subsequent fibrosis (22) . Also, an investigation using a rat model of cisplatin-induced nephrotoxicity revealed that intravenous delivery of hASCs led to lower renal damage and dysfunction, as well as higher survival (24) . Less apoptosis and expression of inflammatory molecules were noted in the kidneys of hASCstreated rats. In addition, renoprotective effects were also observed with the administration of CM from hASCs (24) . Moreover, a recent study showed that preconditioning hASCs with hypoxia increased their beneficial effects on the kidneys of rats with ischemia-reperfusion-induced AKI (45) . Furthermore, in an in vitro study, gene modification of hASCs with hypoxia-inducible factor-1␣ was shown to augment the antiapoptotic effects of hASCs on cisplatin-treated HK-2 human renal cells (42) .
Our present investigation together with the above-mentioned reported studies point to the possibility of further enhancing the renoprotective effects of hASCs in vivo, simply through their in vitro pretreatment with melatonin. Mias et al. (25) demonstrated, using rat marrow-derived MSCs, that their pretreat- ment with melatonin before their injection in rats with ischemia-reperfusion-induced AKI led to higher in vivo survival, antiapoptosis, proliferation of kidney cells, angiogenesis, as well as improved renal function in recipients (25) . When melatonin and untreated cells were similarly administered, findings resembled those seen with untreated cells alone. The authors suggested that it is the intrinsic prosurvival effects of MSCs that are improved by their pretreatment with melatonin (25) . Other than for renal damage, pretreatment of hASCs in vitro with melatonin may also increase the survival and efficacy of these cells in recipients with various other tissue injuries. Since many chemotherapeutic agents including cisplatin exert toxicities to several organs (19) , a further advantage of MSCs such as ASCs in cell therapy applications is their potential for protecting/repairing various organs due to their ability to home to sites of tissue injury (6, 9, 33) . Melatonin pretreatment of cells therefore has the potential to improve their use in different disease models and not just for kidney injury. For instance, a recent investigation by Tang et al. (37) showed that pretreatment of rat bone marrow MSCs with melatonin augmented their survival in vitro in oxidative stress models and decreased their apoptosis following transplantation into ischemic rat brain. The expression of P-Erk 1/2 was found to be raised twofold by melatonin treatment (37) . We observed here also considerably increased expression of P-Erk 1/2, but in hASCs treated with melatonin.
Furthermore, cell types other than ASCs and marrow MSCs can also benefit from melatonin pretreatment. A recent study demonstrated that melatonin pretreatment of murine "early outgrowth" endothelial progenitor cells (eEPCs) enhanced the protective actions of these cells in mice with acute ischemic kidney damage (32) , and that these effects were reversed when cells were instead cotreated with a melatonin receptor antagonist and melatonin. Furthermore, the authors observed in vitro that these eEPCs had a higher migratory ability when pretreated with melatonin (32) . Also, they showed that melatonin could protect against apoptosis/necrosis induced by transforming growth factor-␤. These authors referred to melatonin as a new agonist of EPCs in acute ischemic kidney injury (32) .
In conclusion, our present study shows that when hASCs are used, melatonin pretreatment augments their prosurvival, antioxidative, and antiapoptotic effects, as seen by the ability of their CM to enhance and protect human kidney cells exposed to cisplatin's oxidative and apoptotic toxic effects. Our findings thus suggest that melatonin may increase the clinical effectiveness of hASCs and of their secretome and decrease dose-limiting toxicities of certain chemotherapeutic agents, consequently raising their therapeutic potential. After 42 h, all cells were collected, and lysates were used for Western blotting to determine the expression of P-Erk1/2 and total Erk (A), SOD-1 (B), HO-1 (C), Bcl-2 (D), and GAPDH as a loading control, as described in MATERIALS AND METHODS.
